Dr. Lior Shaltiel reports

IN PREPARATION FOR EXPECTED HUMAN CLINICAL TRIALS, NUREXONE SIGNS AGREEMENT FOR LARGE SCALE PRECLINICAL TESTING FOR ITS SPINAL CORD INJURY THERAPY, EXOPTEN

Nurexone Biologic Inc. has signed a strategic service agreement with Vivox Ltd., a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies. This large-scale animal testing represents a significant step toward filing an investigational new drug (IND) application in the United States for Nurexone's Exopten therapy for spinal cord injury (SCI).

Under the terms of the agreement, Vivox will provide contract research organization (CRO) services to Nurexone, as a prerequisite to commencing human trials under the planned IND. The scope of the services to be provided includes the carrying out of experiments by Vivox on a total of 100 rats, divided into five different experiments. Every experiment involves comprehensive care and monitoring of the rats. In the experiments, some of the test subjects will receive the Exopten active ingredient and a second group will receive a placebo and/or naive exosomes (without the PTEN active ingredient). The typical treatment period is approximately two months. The aim of this series of tests is to evaluate the optimal dosage of Exopten in various pharmacologically relevant rodent models of spinal cord. The agreement underscores both companies' commitment to accelerating innovative therapies for SCI.

"We are pleased to commission Vivox to conduct a series of closely monitored experiments on a large group of laboratory animals as part of the Exopten IND enabling studies. The testing will encompass mobility, behaviour, motor and sensory recovery of rats following spinal cord injury and treatment with Exopten," said Dr. Lior Shaltiel, chief executive officer of Nurexone. "We anticipate that this independent and detailed analysis will corroborate and expand upon the encouraging results observed in numerous laboratory experiments."

Nurexone believes that the Exopten therapy holds significant promise as a potential treatment for SCI. Preclinical studies have demonstrated its ability to promote neural regeneration and functional recovery in animal models. By collaborating with Vivox, Nurexone aims to accelerate the development and regulatory path of Exopten, to bring this potentially transformative treatment to patients in need.

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered central nervous system injuries. The company's first product, Exopten, for acute spinal cord injury, was proven to recover motor function in 75 per cent of laboratory rats when administered intranasally. Exopten has been granted orphan drug designation by the Food and Drug Administration. The Nurexone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

We seek Safe Harbor.